Bile duct cancer (cholangiocarcinoma) is the presence of mutated epithelial cells that originate in the bile ducts. Though, cause of bile duct cancer (cholangiocarcinoma) is not certain. There are several factors that can enhance chances of developing bile duct cancer (cholangiocarcinoma). According to American Society of Clinical Oncology (ASCO), fewer than 3,000 people are affected with the disease annually in the U.S. and around 1,600 people are affected by the disease in the U.K., according to Cancer Research United Kingdom. Major indications of cholangiocarcinoma include abnormal liver function, abdominal pain, weight loss, generalized itching, discoloration of stool and urine etc. Causes of cholangiocarcinoma are not known but factors such as exposure to thorium dioxide, liver fluke infections and cholangitis have been known to increase the chances.
Bile duct cancer (cholangiocarcinoma) treatment market is driven by the technological advancement in healthcare sector and increase in prevalence of cancer patients across the globe. Also, enhanced emphasis of pharmaceutical companies on R&D to come up with potential treatment for bile duct cancer (cholangiocarcinoma). However, high cost associated with latest clinical trials and approvals act as a major barrier for global bile duct cancer (cholangiocarcinoma) treatment market.
Click Here for more information..